EANM、SNMMI与IAEA联合指南:如何建立诊疗一体化中心
该指南由EANM、SNMMI与IAEA联合制定,旨在为有意建立诊疗一体化中心的相关方提供安全启动和运营的框架信息。指南承认全球法规、经济和医疗环境存在差异,但强调全球通用的最佳实践共同要素,不试图回答所有问题,而是作为未来多项细化举措的总体框架。
要点
- 诊疗一体化概念可追溯至上世纪中叶放射性碘首次用于治疗甲状腺疾病。
- SSTR2靶向诊疗一体化在NETTER-1试验后获批,VISION试验阳性结果使其超越核医学领域受到关注。
- 前列腺癌放射性配体治疗的推广需要扩展现有并建立新的诊疗一体化中心。
核心结论
- 该指南试图为相关方安全启动和运营诊疗一体化中心提供有价值的信息。
- 指南不意图回答所有可能问题,而是作为未来多项更详细举措的总体框架。
- 指南承认辐射安全法规的具体内容存在地区差异,但存在全球通用的最佳实践共同要素。
研究设计与样本
- 由EANM、SNMMI与IAEA联合制定的指南。
主要发现
- 放射性碘自首次用于治疗甲状腺疾病以来,已在全球广泛用于良性和恶性甲状腺疾病的诊断成像与治疗。
- SSTR2靶向诊疗一体化在NETTER-1试验后于神经内分泌肿瘤中获批,VISION试验的阳性结果使诊疗一体化超越核医学领域受到关注。
- 治疗高发病率肿瘤如前列腺癌的放射性配体治疗的推广,需要扩展现有和建立新的诊疗一体化中心。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The theranostics concept using the same target for both imaging and therapy dates back to the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. Since then, radioiodine has become broadly established clinically for diagnostic imaging and therapy of benign and malignant thyroid disease, worldwide. However, only since the approval of SSTR2-targeting theranostics following the NETTER-1 trial in neuroendocrine tumours and the positive outcome of the VISION trial has theranostics gained substantial attention beyond nuclear medicine. The roll-out of radioligand therapy for treating a high-incidence tumour such as prostate cancer requires the expansion of existing and the establishment of new theranostics centres. Despite wide global variation in the regulatory, financial and medical landscapes, this guide attempts to provide valuable information to enable interested stakeholders to safely initiate and operate theranostics centres. This enabling guide does not intend to answer all possible questions, but rather to serve as an overarching framework for multiple, more detailed future initiatives. It recognizes that there are regional differences in the specifics of regulation of radiation safety, but common elements of best practice valid globally.
引用
- Herrmann K, Giovanella L, Santos A, et al. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. Eur J Nucl Med Mol Imaging. 2022. PMID: 35403861. doi:10.1007/s00259-022-05785-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。